Clay Thorp - May 19, 2022 Form 4 Insider Report for PhaseBio Pharmaceuticals Inc (PHASQ)

Role
Director
Signature
/s/ John P. Sharp, Attorney-in-fact
Stock symbol
PHASQ
Transactions as of
May 19, 2022
Transactions value $
$0
Form type
4
Date filed
5/20/2022, 04:46 PM
Previous filing
May 17, 2022
Next filing
Jun 24, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PHASQ Non-employee Director Stock Option (right to buy) Award $0 +17.5K $0.00 17.5K May 19, 2022 Common Stock 17.5K $0.84 Direct F1
transaction PHASQ Restricted Stock Units Award $0 +3.75K $0.00 3.75K May 19, 2022 Common Stock 3.75K Direct F2, F3

Explanation of Responses:

Id Content
F1 The shares subject to the option shall vest on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of PhaseBio Pharmaceuticals, Inc. common stock.
F3 The RSUs shall vest and be delivered to the Reporting Person on the earlier of the one-year anniversary of the grant date or the 2023 annual stockholder meeting, subject to the Reporting Person's continuous service through such date.